Cardio-hepatic syndrome in patients undergoing transcatheter aortic valve replacement.
Lukas StolzMichael KirchnerJulius SteffenPhilipp M DoldiDaniel BraunLudwig T WeckbachThomas J StockerKornelia LöwJulius FischerMagda HaumHans D TheissKonstantinos RizasMartin OrbanSven PeterßMichael NäbauerSteffen MassbergJörg HausleiterSimon DeseivePublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2023)
In patients undergoing TAVR, CHS is prevalent in 22% of patients and is associated with increased postinterventional mortality. Thus, CHS should be included in the decision-making process within the TAVR heart team. Cardiohepatic syndrome (CHS) as defined by an elevation of at least two of three laboratory cholestasis parameters above the upper limit of normal was prevalent in 22% of patients undergoing TAVR for severe AS. The presence of CHS was associated with more severe heart failure symptoms and worse three-year survival.
Keyphrases
- transcatheter aortic valve replacement
- patients undergoing
- aortic stenosis
- aortic valve
- ejection fraction
- heart failure
- decision making
- end stage renal disease
- left ventricular
- drug induced
- peritoneal dialysis
- case report
- early onset
- prognostic factors
- newly diagnosed
- cardiovascular events
- atrial fibrillation
- palliative care
- cardiovascular disease
- type diabetes
- patient reported outcomes
- quality improvement
- acute heart failure